Pms24 - Cost Minimization Analysis of Third Line Rheumatoid Arthritis Drugs in Ecuador

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1738
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Impact of Price Regulation of Biologic Therapies for Rheumatoid Arthritis in Colombia – A Cost Minimization Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Cost-Effectiveness Analysis of Tocilizumab Subcutaneouscombotherapy First Line for the Management of Rheumatoid Arthritis in Greece

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Cost-Minimization Analysis of Anti-TNF Biologics in the Treatment of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriatic Arthritis Under the Brazilian Private Health Care System Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Safety, Cost and Effectiveness Issues With Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1999English

Anti-Inflammatory Drugs for Rheumatoid Arthritis

BMJ
1976English

Cost Effectiveness of TNF-αInhibitors in Rheumatoid Arthritis

International Journal of Inflammation
AllergyImmunology
2013English

Pms44 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pms56 - Cost-Effectiveness Analysis of Subcutaneous Tocilizumab Without Methotrexate in Rheumatoid Arthritis Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy